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Abstract 
Purpose: To evaluate the efficacy and tolerability of chemotherapy, a geriatric assessment is 
recommended in elderly patients with cancer. We aimed to characterize and compare 
patients with aggressive lymphoma by objective response and survival status based on pre-
treatment cancer-specific geriatric (C-SGA) and quality of life (QoL) assessments. 
Methods: Patients not eligible for anthracycline-based first-line therapy or intensive salvage 
regimens completed a cancer-specific geriatric (C-SGA) and quality of life (QoL) assessment 
before and after a rituximab-bendamustine-lenalidomide (R-BL) treatment in a phase II 
clinical trial. Clinical outcomes were compared based on pre-treatment individual and 
summary C-SGA measures, their cut-off-based subcategories and QoL indicators, using 
Wilcoxon rank sum or Chi-Square tests. 
Results: A total of 57 patients (41 included in the clinical trial) completed a C-SGA. 
Participants with pre-treatment impaired functional status (Vulnerable Elders Survey-13 
score ≥ 3) were more likely to experience worse outcomes: a higher proportion were non-
responders, died before the median follow-up of 31.6 months (interquartile range [IQR] 27.9-
37.9) or died during treatment. Non-responders were patients categorized as having possible 
depression (Geriatric Depression Scale-5 score ≥ 2) and with worse QoL scores for 
functional performance. Patients with worse C-SGA summary scores and with greater 
tiredness were more likely to die during treatment.  
Conclusion: A pre-treatment impaired functional status is an important factor with respect to 
clinical outcomes in patients receiving an R-BL regimen. Individual geriatric and related QoL 
domains showed similar associations with clinical outcomes. Whether interventions targeting 
specific geriatric dimensions also translate in better symptom- or domain specific QoL 
warrants further research. 
 
Key words: Aggressive B-cell lymphoma, Geriatric assessment, quality of life, rituximab-
bendamustine-lenalidomide treatment  
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Introduction 
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin 
lymphoma (NHL) in older patients [25]. Incidence rates are increasing especially in those > 
60 years of age [36]. Older patients with cancer are a heterogeneous population with regard 
to daily functioning, comorbidities, disabilities and geriatric conditions [12, 16]. In 60 to 70% 
of NHL patients > 60 years, comorbid conditions are common with the consequence that 
many of these patients are not eligible for randomized clinical trials [24]. Trials specifically 
designed for older cancer patients do often not address endpoints that are relevant for this 
population [48]. The impact of treatment on quality of life (QoL), functional capacities, 
cognition, and social situation may be more important than the prolongation of life. Older 
cancer patients tend to weight their QoL as more important than gain in survival compared to 
younger patients [31, 45]. Information on QoL in DLBCL patients are predominantly from 
studies on survivors at all ages [28, 43], which may not adequately reflect QoL in patients 
who have a poorer prognosis or are unfit to receive standard treatment.  
A comprehensive geriatric assessment (CGA) defined as a multidimensional diagnostic 
process to determine an older person’s medical, psychosocial, and functional capabilities, is 
recommended to evaluate the efficacy and tolerability of chemotherapy in older cancer 
patients is [47]. There is growing evidence that several domains are associated with 
treatment toxicity, mortality and treatment decision-making [33]. In studies with older or unfit 
patients with DLBCL, a CGA has been used to prospectively identify frail patients [23], 
patients who can benefit from a curative approach [41, 42] or to modify chemotherapy [29, 
39]. 
In settings where so-called standard treatment therapy is not feasible, and the proportion of 
older patients is increasing, meaningful outcomes as represented by the different dimensions 
of a CGA and QoL should be mandatory [48]. We aimed to characterize and compare 
patients with aggressive B-cell lymphoma receiving a rituximab, bendamustine and 
lenalidomide (R-BL) regimen [17] by response and survival status based on pre-treatment 
cancer-specific geriatric (C-SGA) and QoL assessments. We also report on changes in C-
SGA and QoL from pre- to post-treatment and characterize and compare patients registered 
vs. those not registered to the phase II trial based on C-SGA and QoL. 
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Methods 
This was an open-label, prospective, multicenter phase II clinical trial designed to investigate 
the efficacy and tolerability of an R-BL regimen in patients not eligible for anthracycline-
based first-line therapy or intensive salvage regimens. Patients with histologically confirmed 
aggressive non-Hodgkin lymphoma including DLBCL, transformed follicular lymphoma (FL), 
or FL grade 3b according to the WHO classification were enrolled in 12 Swiss centers from 
August 2011 to January 2014. Details on eligibility criteria are described elsewhere [17]. For 
response assessment, criteria of the International Working Group for evaluation of response 
in non-Hodgkin’s Lymphoma were used. Response was defined as complete response, 
unconfirmed complete response or partial response (CR/CRu+PR) [8]. 
The study was conducted in compliance with the Declaration of Helsinki and the International 
Conference on Harmonization Good Clinical Practices. Ethical approval was obtained from 
the ethics committee and institutional review board for each site and patients provided 
separate written informed consent for C-SGA and QoL assessments [17]. The study was 
registered with ClinicalTrials.gov, number NCT00987493. 
Assessments 
All patients were required to undergo a cancer-specific geriatric assessment (C-SGA) and to 
complete a QoL form before treatment start, at day 1 of each cycle and within 1 month after 
completing treatment. 
The C-SGA was developed by the Swiss Group for Clinical Cancer Research (SAKK C-SGA) 
for specific use in clinical trials including older patients applying a mix of medical record 
abstraction and patient interview. Feasibility was confirmed in a cross-sectional study of 
cancer patients presenting for initiation of chemotherapy treatment [9]. The SAKK C-SGA 
consists of six standard geriatric assessment measures [16] covering the domains: 
comorbidity, functional status, psychosocial including depression and social support, 
nutrition, and cognition (Table 1). From these measures six individual scores and one 
summary score is obtained (varying scales range from 0–5 to 1–100). Continuous individual 
measure scores are dichotomized based on the individual measure’s established cut-off. The 
summary SAKK C-SGA score is calculated by summing the number of ‘deficit’ scores in each 
of the 5 domains (range from 0–5), and dichotomizing deficits as ≤2 (low risk) vs. ≥3 (at risk) 
for poor outcomes using known cut-points of deficits [10]. 
 
The QoL assessment included five global QoL domains related to the C-SGA domains for 
physical wellbeing, mood, coping effort, functional performance, and overall treatment 
burden [3, 6], and three indicators specific to side-effects (tiredness, nausea/vomiting, taste 
disturbances) [11]. Physical wellbeing, mood and functional performance represent the 
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physical, emotional and functional domain of most multi-dimensional cancer-related QoL 
measures. All QoL scales were measured by single-item visual analogue scales ranging from 
0-100. Higher scores indicate a worse condition.  
 
Analysis 
Pre-treatment summary and individual C-SGA measures, their subcategories based on 
respective cut-offs, and QoL indicators were compared for the following clinical outcomes: 
response, survival status (dead or alive at the time of the analysis), time point of death 
(during vs. after treatment), and study participation. The Wilcoxon rank sum and Chi-Square 
tests were used for continuous and categorical variables, respectively. Post- and pre-
treatment C-SGA and QoL assessments were compared using the Wilcoxon signed-rank test 
for continuous, and McNemar's or Bowker's test of symmetry for categorical variables. The 
Kaplan-Meier curve of overall survival is presented for the pre-treatment scores showing an 
impact on survival status. No adjustment was made for multiple testing due to the exploratory 
nature of this study. 
 
Results 
A total of 57 patients completed a pre-treatment C-SGA, among those 41 were included in 
the study (Fig 1). 
 
Patient and disease characteristics are shown in Table 2. Median age was 75 (min-max: 40–
94) years with 83% of the patients being older than 65 years. A majority (80%) had a 
Charlson Comorbidity Index (CCI) score of more than 4 (80%), a performance status of 0 or 
1 (85%), presented with advanced stage disease (63%) and had an international prognostic 
index (IPI) of low/low-intermediate risk status (54%). The median follow-up was 31.6 (IQR 
27.9-37.9) months at the time point of trial termination. Older patients (≤ 75 vs. >75) had a 
higher CCI, and C-SGA summary score, and reported less nausea. Patients with a higher 
performance status (0 or 1 vs. ≥2) had higher Vulnerable Elders Survey-13 (VES-13) scores 
and C-SGA summary scores. Patients with an IPI of high or high-intermediate risk reported 
worse physical well-being than those with a low or low-intermediate risk (data not shown). 
 
Table 3 displays the pre-treatment C-SGA and QoL scores by response. A higher proportion 
of patients who did not achieve CR/CRu+PR had an impaired functional status (VES-13 
score ≥3; 63% vs. 24%, p=0.014), possible depression (GDS-5 score ≥2; 38% vs. 8%, 
p=0.020), and reported lower functional performance (median (min-max) = 33 (1-97) vs. 13 
(2-99), p=0.045). For all other C-SGA and QoL domains no significant differences were found 
between the two response groups before treatment start.  
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Among the 25 patients who had a normal functional status at baseline, 14 completed all 6 
cycles of therapy, while none out of 16 patients with impaired functional status completed all 
six cycles (Table S1). Six patients needed a dose reduction for bendamustine and 10 
patients for lenalidomide, with similar proportion in patients with and without impaired 
functional status (data not shown).  
 
Pretreatment scores for C-SGA and QoL by survival status (Table 4) differed in functional 
status. A higher proportion of patients who had died had pre-treatment impaired functional 
status (53% vs. 0%, p=0.003) compared to those who were still alive. The Kaplan-Meier 
curve of overall survival according to the pre-treatment scores for functional status is 
presented in Figure 2. 
 
A higher proportion of patients who died during treatment versus those who died during 
follow-up (table S2 supplemental material) had pre-treatment impaired functional status (89% 
vs. 38%, p=0.011), and poor outcomes (C-SGA summary score; 78% vs. 33%, p=0.025), 
and reported worse tiredness (median (min-max) = 90 (16-100) vs. 59 (2-92), p=0.002). 
 
Comparisons of pre-treatment C-SGA and QoL scores between patients who were registered 
and those who were not registered to the trial (table S3 supplemental material) showed that 
in a greater proportion of registered patients depression was unlikely (80% vs. 38%, 
p=0.002). Registered patients also reported higher scores in the Mini Nutritional Assessment 
(MNA) indicating a better nutritional status (median (min-max) = 10 (5-13) vs. 8.5 (3-12), 
p=0.020; for total score), less taste disturbance (median (min-max) = 6 (0-90) vs. 24 (1-89), 
p=0.012), and less anticipated treatment burden (median (min-max) = 10 (0-67) vs. 46 (0-
94), p=0.046). 
 
Significant changes from pre- to post-treatment assessments were found for the function and 
nutrition domains (Figure S1 supplemental material). The proportion of patients who had 
impaired functional status increased from 21% to 46% (p=0.014). Scores for nutrition 
worsened (from median (min-max) = 11 (6-13) to 9 (5-12), p=0.008). This is also reflected in 
the overall C-SGA score with a trend to a higher proportion of patients becoming at risk for a 
poor outcome after the end of treatment (p=0.059). The effort to cope with the disease 
decreased from pre- to post-treatment (p=0.042; Figure S2 supplemental material). 
 
Discussion 
Pre-treatment geriatric assessment of older patients with aggressive B-cell lymphoma is 
important to determine potential treatment tolerance and to restore or prevent health or QoL 
decline [24]. In our population of patients receiving a R-BL regimen, we found worse clinical 
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outcomes for patients who had impaired functional status before treatment start. This 
geriatric domain was the only among five domains that was related to response, survival 
status, and time point of death. Non-responders were also patients categorized as having 
possible depression, and patients with worse C-SGA summary scores were more likely to die 
during treatment.  
Our results are in line with several studies that identified loss of function in activities of daily 
living (ADL) to be a predictor of survival in older patients with DLBCL [27, 39, 49]. A larger 
study with a mixed cancer population including patients with non-Hodgkin lymphoma 
reported also that poor mobility was a risk factor for early death [37]. Other studies in this 
population examined the response rate [29, 41] and survival [39, 42, 49] of patients 
categorized as frail, unfit, or fit rather than according to individual dimensions of the geriatric 
assessment. Tucci et al [41] found response rate to be significantly higher in patients 
considered as ‘fit’ compared with ‘unfit’ patients. Similar to the study of Olivieri et al [29], who 
found no significant difference in the response rate between patients considered as ‘fit’, ‘unfit’ 
or ‘frail’, we found that the characterisation of patients ‘at risk’ vs. ‘not at risk’ for poor 
outcome was not significantly associated with response. In our sample, possible depression 
was associated with response but not with survival status. This is in contrast to a recent 
study showing that emotional disorders had a negative effect on overall survival in older 
patients with advanced ovarian cancer [40]. 
Patients not registered compared to those registered to the study had a higher risk for 
depression and malnutrition. Although we had fewer patients than anticipated in the group of 
patients not registered to the study with a pre-treatment C-SGA assessment available, 
psychological and nutritional state may be factors that influence the decision whether or not 
to include patients in the study. Limited information exists on the impact of a pre-treatment 
CGA on the cancer treatment plan [32]. Similar to our findings, Girre et al [14] reported the 
absence of depressive symptoms and body mass index to be associated with a modification 
of the treatment plan, whereas Chaibi et al [7] found that more frequent severe comorbidities 
and dependence for at least one ADL led to delay in or less intensive treatment in cancer 
patients older than 70 years.  
Pre-treatment QoL indicators for functional performance and tiredness were significantly 
related to the clinical outcomes. Taste disturbance and treatment burden were associated 
with a patient’s registration to the study. The significant associations of specific individual 
QoL indicators and geriatric domains with the clinical outcomes show a similar pattern. 
Targeting specific geriatric dimensions may also translate in better symptom- or domain 
specific QoL in a population of patients to whom QoL is more important than gains in survival 
[31, 45]. Studies in older cancer patients receiving chemotherapy showed that function and 
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co-morbidity were independent predictors of QoL [46] and that those patients identified as 
frail by a CGA had significantly worse global QoL [19]. A small pilot study found that a CGA 
with structured multi-disciplinary follow-up according to risk resulted in improved QoL scores 
in older breast cancer patients [13]. 
Changes in C-SGA domains and QoL indicators from pre- to post treatment indicate a 
significant worsening in the overall C-SGA score probably driven by the significant worsening 
in functional and nutritional status post-treatment. Despite these deteriorations, patients 
reported less effort to cope with the disease over time. This may indicate an adaptation to the 
disease considering that the psycho-social and cognitive components of the geriatric 
assessment remained stable over the course of treatment. A comparison of our results with 
existing studies is difficult because changes in geriatric dimension over time have rarely been 
reported [32]. In older breast cancer patients, one study reported an increase from an 
average of six to nine geriatric problems over a 6-month follow-up period [13], while another 
study found that women maintained their baseline ability to perform ADLs after 6 months 
despite remarkable toxicity of the chemotherapy received [18]. No changes in functional but 
improvements in symptom-specific and global QoL have been reported in patients with 
DLBCL who were treated with progressive [22] or cautious treatment [22, 38]. 
A strength of our study is that we assessed all components of a C-SGA including not only 
daily functioning and comorbidities, but also nutritional status, cognitive function, 
psychological state and social support [24]. The concurrent assessment of C-SGA and QoL 
components allowed observation of parallels between these two constructs. Without the 
characterization of older patients included in clinical trials by CGA and QoL status, the 
extrapolation of study results to the general older cancer population is limited [48]. A further 
strength is the inclusion of a post-treatment C-SGA facilitating investigation of changes in 
individual C-SGA and QoL components over the course of treatment. This is rare in phase II 
trials in general, and specifically in patients with DLBCL [33]. 
Limitations include that the age of patients was not restricted to older patients as initially 
intended. The number of participants younger than 60 years (n=5) was small and the results 
of a sensitivity analysis excluding these patients were similar. The VES-13 is not a pure 
functional assessment tool such as ADL or any of the direct functional measures [30]. It 
includes the patient’s estimation of his or her own health, and the age of > 85 years is 
considered a criterion for vulnerability by itself. However, the VES-13 covers only one 
dimension of a CGA. It is considered as useful and accurate when diagnosing impaired 
functional status [20, 21]. Changes over time were only reported for patients who completed 
the second assessment, which may have introduced a bias towards underestimating the 
impact of treatment on geriatric and QoL domains. Due to the small study sample we cannot 
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exclude that other than the reported domains may be associated with clinical outcomes. No 
specific tool for a CGA is recommended [24] and the number of geriatric domains and 
corresponding measures vary in clinical studies, which limits the comparison of our results 
with those of other studies.  
Although some studies in other types of cancer have assessed both C-SGA and QoL [1, 4, 
13, 18, 19, 33, 46], future research is needed to study geriatric and QoL dimensions 
concurrently, and to investigate their interplay in order to obtain information how to tailor 
geriatric interventions to ultimately improve QoL of older patients. Prospective studies for 
older patients with aggressive B-cell lymphoma incorporating a broader coverage of CGA 
domains are necessary. 
In conclusion, our results suggest that pre-treatment impaired functional status based on the 
VES-13 cut-off is an important factor with respect to clinical outcomes in patients not eligible 
for anthracycline-based first-line therapy or intensive salvage regimens. Individual geriatric 
domains and related QoL indicators showed similar associations with clinical outcomes. 
Whether interventions targeting specific geriatric dimensions also translate in better 
symptom- or domain specific QoL warrants further research. 
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Figure 1 CONSORT flowchart  
 
  
Baseline (pre-treatment) 
C-SGA and QoL assessment 
(n=57) 
Registered to the study 
(n=41) 
Not registered to the study 
(n=16)  
• Eligible for anthracycline-based treatment 
(n=1) 
• Relapse not confirmed (n=1) 
• Inadequate haematological values, renal, 
hepatic or cardiovascular function (n=14) 
Follow-up C-SGA and QoL 
assessment 
(n=24) 
No follow-up C-SGA and 
QoL assessment 
(n=17)  
 
• Died before follow-up 
assessment (n=8) 
• Too ill to participate in C-
SGA/QoL (n=3) 
• C-SGA/QoL not conducted by 
staff (n=6) 
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Figure 2 Kaplan-Meier curve of overall survival 
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Table 1 Content and operationalization of the SAKK Cancer-Specific Geriatric 
Assessment (C-SGA) and related QoL indicators 
Assessment 
Domain  
Assessment Tool  Administration  Range: Cutoff  QoL indicatora 
Comorbidity Charlson Comorbidity 
Index (CCI)[15] 
Medical Record 
Abstraction (MRA) 
0-43: ≥4 
 
 
Functional status  Vulnerable Elders 
Survey (VES-13)[35] 
Interviewer 
administered  
0-10: ≥3 Physical Well-being 
[6] 
Functional 
Performance [2] 
Psychosocial  
 
Geriatric Depression 
Scale 5-item short 
form (GDS-5)[34] 
Interviewer 
administered  
0-5: ≥2  Mood 
Coping[6] 
 Modified MOS- Social 
Support Survey 
(mMOS-SS)[26] 
Interviewer 
administered  
 
0-8: ≤2.5   
Nutrition  Mini Nutritional 
Assessment (MNA)[44] 
Interviewer 
administered and 
MRA  
0-14: ≤11 Nausea/vomiting 
Taste disturbance 
[11] 
Cognition  Mini Cog[5]  Interviewer 
administered  
Cognitive impairment: 
0-2 words recalled and 
abnormal clock drawing 
test 
Normal cognitive 
function: 1-3 words 
recalled and normal 
clock drawing test 
 
 
5 Domains Six Measures: CCI, 
VES-13, GDS-5, 
mMOS-SS, MNA, Mini-
Cog 
Interviewer 
administered, MRA 
0-5: ≥3 deficits [10]  
aAll QoL indicators range from 0 to 100 with higher scores representing a worse condition. 
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Table 2 Patient and disease characteristics 
 All patients 
 
(N=41) 
Sex 
Male 
Female 
 
24 (59%) 
17 (41%) 
Age (years) 75 (40, 94) 
Charlson Comorbidity Index 
2-4 
> 4 
Cardiovascular diseases 
Diabetes 
 
8 (20%) 
33 (80%) 
20 (49%) 
8 (20%) 
WHO performance status  
0 
1  
≥ 2 
 
15 (37%) 
20 (49%) 
6 (15%) 
Bone marrow involved 5 (12%) 
Extranodal involvement  
0 
1 
2 
≥ 3 
 
12 (29%) 
15 (37%) 
9 (22%) 
5 (12%) 
Ann Arbor stage  
I 
II  
III 
IV 
 
3 (7%) 
12 (29%) 
6 (15%) 
20 (49%) 
IPI 
Low (0-1) 
Low-intermediate (2) 
High-intermediate (3) 
High (4-5) 
Missing 
 
8 (20%) 
14 (34%) 
11 (27%) 
7 (17%) 
1 (2%) 
First-line treatment 13 (32%) 
Prior lines of therapy 
1 
2 
≥ 3 
 
11 (27%) 
8 (20%) 
9 (22%) 
Histologic subtypes 
Diffuse large B-cell lymphoma 
Follicular lymphoma  grade 3b  
Transformed follicular lymphoma 
Mantle cell lymphoma 
 
35 (85%) 
3 (7%) 
2 (5%) 
1 (2%) 
C-SGA summary score 
High risk for poor outcome 
Low risk for poor outcome 
 
16 (39%) 
25 (61%) 
Quality of life indicatorsa 
Physical well-being 
Mood 
Functional performance 
 
24 (1, 92) 
22 (0, 86) 
23 (1, 99) 
Data are number of patients (%) or median (min, max) 
aPhysical well-being,mood and functional performance were selected to cover three standard domains of most 
multi-dimensional cancer-related QoL measures 
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Table 3 Baseline (pre-treatment) C-SGA and QoL scores by response 
 
CR/CRu and PR not 
achieved 
(N=16) 
CR/CRu or PR achieved 
(N=25) p-valuea 
Charlson Comorbidity Index (CCI) 5.5 (2.0, 10.0) 6.0 (4.0, 11.0) 0.314 
.     ≥4 (severe comorbidity) 13 (81%) 25 (100%) 0.025 
.     1-3 (average comorbidity) 3 (19%) 0 (0%)  
Vulnerable Elders Survey (VES-13) 4.0 (1.0, 9.0) 1.0 (0.0, 7.0) 0.004 
.     ≥3 (impaired functional status) 10 (63%) 6 (24%) 0.014 
.     <3 (normal functional status) 6 (38%) 19 (76%)  
Geriatric Depression Scale (GDS-5)  1.0 (1.0, 3.0) 1.0 (0.0, 4.0) 0.002 
.     ≥2 (depression possible) 6 (38%) 2 (8%) 0.020 
.     0-1 (depression unlikely) 10 (63%) 23 (92%)  
Modified Medical Outcomes Study Social 
Support Survey (mMOS-SS) 4.6 (3.5, 5.0) 4.8 (2.1, 5.0) 0.723 
.     ≤2.5 (at risk for social isolation) 0 (0%) 3 (12%) 0.150 
.     > 2.5 (no risk for social isolation) 16 (100%) 22 (88%)  
Mini Nutritional Assessment (MNA)  9.5 (5.0, 12.0) 11.0 (6.0, 13.0) 0.218 
.     ≤ 11 (at risk for malnutrition) 12 (75%) 18 (72%) 0.833 
.     ≥12 (normal nutritional status) 4 (25%) 7 (28%)  
Cognitive function test (Mini Cog)      0.833 
.     Cognitive impairment 4 (25%) 7 (28%)  
.     No cognitive impairment 12 (75%) 18 (72%)  
C-SGA Summary Score 2.5 (1.0, 4.0) 2.0 (1.0, 4.0) 0.459 
.     ≥ 3 deficits (at risk for poor outcomes) 8 (50%) 8 (32%) 0.249 
.   0- 2 deficits (low risk of poor outcomes) 8 (50%) 17 (68%)  
Physical wellbeing 24.5 (1.0, 72.0) 22.0 (2.0, 92.0) 0.915 
Mood 34.0 (0.0, 86.0) 19.0 (2.0, 84.0) 0.512 
Coping effort 43.0 (2.0, 90.0) 30.0 (3.0, 95.0) 0.407 
Functional performance 33.0 (1.0, 97.0) 13.0 (2.0, 99.0) 0.045 
Treatment burden 16.0 (0.0, 67.0) 7.5 (0.0, 59.0) 0.521 
Tiredness 68.0 (7.0, 98.0) 49.0 (2.0, 100.0) 0.214 
Nausea/vomiting 7.0 (0.0, 80.0) 4.0 (0.0, 47.0) 0.243 
Taste disturbance 9.0 (0.0, 48.0) 5.0 (0.0, 90.0) 0.510 
 
Data are median (min, max) or number of patients (%), unless otherwise stated. 
aWilcoxon rank sum test for continuous variables / Chi-Square test for categorical variables, p-values were 
calculated for total scores and for cut-offs for each geriatric domain, if applicable. 
CR/CRu: Complete response/complete response unconfirmed 
PR: Partial response 
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Table 4 Baseline (pre-treatment) C-SGA and QoL scores by survival statusa 
Variable 
Alive 
(N=10) 
Dead 
(N=30) p-valueb 
Charlson Comorbidity Index (CCI)  5.0 (4.0, 7.0) 6.0 (2.0, 11.0) 0.057 
.     ≥4 (severe comorbidity) 10 (100%) 27 (90%) 0.299 
.     1-3 (average comorbidity 0 (0%) 3 (10%)  
Vulnerable Elders Survey (VES-13)  1.0 (0.0, 2.0) 3.0 (0.0, 9.0) 0.006 
.     ≥3 (impaired functional status) 0 (0%) 16 (53%) 0.003 
.     <3 (normal functional status) 10 (100%) 14 (47%)  
Geriatric Depression Scale (GDS-5)  1.0 (0.0, 4.0) 1.0 (0.0, 3.0) 0.220 
.     ≥2 (depression possible) 1 (10%) 7 (23%) 0.361 
.     0-1 (depression unlikely) 9 (90%) 23 (77%)  
Modified Medical Outcomes Study Social 
Support Survey (mMOS-SS) 4.2 (2.4, 5.0) 4.9 (2.1, 5.0) 0.146 
.     ≤2.5 (at risk for social isolation) 2 (20%) 1 (3%) 0.083 
.    > 2.5 (o risk for social isolation) 8 (80%) 29 (97%)  
Mini Nutritional Assessment (MNA)  11.5 (7.0, 13.0) 9.5 (5.0, 12.0) 0.008 
.     ≤ 11 (at risk for malnutrition) 5 (50%) 24 (80%) 0.066 
.     ≥12 (normal nutritional status) 5 (50%) 6 (20%)  
Cognitive function test (Mini Cog)      0.540 
.     Cognitive impairment 2 (20%) 9 (30%)  
.     No cognitive impairment 8 (80%) 21 (70%)  
C-SGA Summary Score 1.5 (1.0, 3.0) 2.0 (1.0, 4.0) 0.022 
.    ≥3 deficits (at risk for poor outcomes) 2 (20%) 14 (47%) 0.136 
.     0-2 deficits (low risk of poor outcomes) 8 (80%) 16 (53%)  
Physical wellbeing 12.0 (3.0, 77.0) 25.5 (2.0, 92.0) 0.417 
Mood 17.0 (2.0, 84.0) 31.5 (2.0, 86.0) 0.553 
Coping effort 16.5 (5.0, 54.0) 38.5 (2.0, 95.0) 0.092 
Functional performance 8.5 (2.0, 87.0) 25.0 (1.0, 99.0) 0.260 
Treatment burden 7.0 (5.0, 67.0) 16.0 (0.0, 59.0) 0.689 
Tiredness 31.5 (3.0, 95.0) 65.0 (2.0, 100.0) 0.138 
Nausea/vomiting 5.5 (1.0, 32.0) 4.5 (0.0, 80.0) 0.900 
Taste disturbance 6.0 (1.0, 21.0) 6.0 (0.0, 90.0) 0.699 
 
Data are median (min, max) or number of patients (%), unless otherwise stated. 
aafter median follow-up of 31.6 months 
bWilcoxon rank sum test for continuous variables / Chi-Square test for categorical variables; p-values were 
calculated for total scores and for cut-offs for each geriatric domain, if applicable. 
 
 
